| P2093 | author name string | Igor J Koralnik | |
| | Dusan Stefoski | |
| | Roumen Balabanov | |
| | Fabian Sierra Morales | |
| | Michael Ko | |
| | Rasha Waheed | |
| P2860 | cites work | Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation | Q26779416 |
| | G-CSF and GM-CSF in Neutropenia | Q26800954 |
| | The human polyomavirus, JCV, uses serotonin receptors to infect cells | Q28294207 |
| | Multiple sclerosis | Q28299151 |
| | Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry | Q28555138 |
| | PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression | Q29618956 |
| | PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 |
| | Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis | Q30659100 |
| | PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids | Q33398308 |
| | Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome | Q33773622 |
| | Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis | Q34089586 |
| | JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene | Q34112987 |
| | Outcome and survival of asymptomatic PML in natalizumab-treated MS patients | Q34562841 |
| | Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. | Q34891171 |
| | Determinants of survival in progressive multifocal leukoencephalopathy | Q35012056 |
| | Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS | Q35938575 |
| | Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy | Q36103979 |
| | T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. | Q36215165 |
| | Tissue expression of PD-L1 mediates peripheral T cell tolerance. | Q36228541 |
| | Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance | Q36318980 |
| | A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes | Q37135539 |
| | Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function | Q37180600 |
| | Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice | Q37209245 |
| | Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome | Q37313729 |
| | Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort | Q37380300 |
| | Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases | Q37714089 |
| | Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy? | Q38752797 |
| | No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. | Q38754429 |
| | Identification and characterization of mefloquine efficacy against JC virus in vitro | Q39877627 |
| | G-CSF enhances the adhesion of encephalitogenic T cells to extracellular matrix components: a possible mechanism for exacerbation of multiple sclerosis | Q40334848 |
| | Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS. | Q42144320 |
| | Comment: avoiding detrimental effects of corticosteroids on JC virus T-cell responses--primum non nocere | Q44719955 |
| | The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy | Q47238417 |
| | Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS. | Q47344550 |
| | Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor | Q47590532 |
| | To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. | Q47812653 |
| | G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases | Q47992512 |
| | Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? | Q53132815 |
| | Progressive multifocal leukoencephalopathy after interferon beta-1a monotherapy | Q57514485 |
| | Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells | Q84189848 |
| | Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial | Q95823071 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 923-931 | |
| P577 | publication date | 2019-05-01 | |
| P1433 | published in | Annals of clinical and translational neurology | Q27725312 |
| P1476 | title | Treatment of natalizumab-associated PML with filgrastim | |
| P478 | volume | 6 | |